Seer (SEER) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Apr, 2026Executive summary
Received a highly contingent, non-binding, unsolicited acquisition proposal from Radoff-JEC Group to acquire all outstanding Class A common stock for $2.25 per share in cash plus a contingent value right.
Board will review the proposal with independent financial and legal advisors to determine the best course of action for all stockholders.
No stockholder action is required at this time; the Board's formal recommendation will be provided in the definitive proxy statement.
Forward-looking statements caution that actual results may differ due to risks and uncertainties.
Voting matters and shareholder proposals
Radoff-JEC Group nominated three director candidates for election at the 2026 Annual Meeting.
The Corporate Governance and Nominating Committee will review the nominees per company bylaws.
The Board will present its recommendation on the nominations in the definitive proxy statement for the 2026 Annual Meeting.
Board of directors and corporate governance
Current board members include Omid Farokhzad, Meeta Gulyani, Robert Langer, Terrance McGuire, Deep Nishar, Isaac Ro, Nicolas Roelofs, and David Horn.
Additional information on board members and their interests will be included in the 2026 Proxy Statement.
The Corporate Governance and Nominating Committee is responsible for reviewing director nominations.
Latest events from Seer
- Acquisition proposal and board nominations prompt detailed review ahead of 2026 Annual Meeting.SEER
Proxy filing13 Apr 2026 - Strong growth, innovation, and new detector tech set the stage for future expansion.SEER
TD Cowen 46th Annual Health Care Conference4 Mar 2026 - 2025 revenue rose 17% to $16.6M, with improved margins and a 67% increase in installed base.SEER
Q4 202526 Feb 2026 - Q2 revenue fell 23% to $3.1M; guidance cut, but cash remains strong and pipeline is growing.SEER
Q2 20242 Feb 2026 - High-impact publications and scientific validation drive optimism for growth in 2025.SEER
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 20242 Feb 2026 - Proteograph's robust, scalable platform accelerates unbiased biomarker discovery and scientific adoption.SEER
Morgan Stanley 22nd Annual Global Healthcare Conference22 Jan 2026 - Q3 revenue fell 3% to $4.0M; net loss was $21.3M; new Thermo Fisher partnership announced.SEER
Q3 202416 Jan 2026 - Proteograph's scale and partnerships are accelerating unbiased proteomics adoption and discovery.SEER
Guggenheim Securities Inaugural Healthcare Innovation Conference15 Jan 2026 - Accelerating global adoption and innovation in deep proteomics drive strong 2025 outlook.SEER
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026